Nektar Therapeutics (NKTR) and partner AstraZeneca (AZN) announced after the close Thursday that the majority of FDAQ Anesthetic and Analgesic Drug Products Advisory Committee members voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist class of drugs. This includes MOVANTIKTM, an investigational treatment for opioid-induced constipation for patients with chronic non-cancer pain.
Nektar Therapeutics was range-bound throughout Thursday's session and finished with a gain of 0.30 at $12.54. The stock is now up 1.34 on 96K shares after the bell.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.